BioStock: SynAct comments on positive Phase II data

Yesterday, preliminary data from SynAct Pharma’s Phase II study with the drug candidate AP1189 in patients with rheumatoid arthritis was released. The data indicate that AP1189, administered in doses of 50 mg, is safe and well-tolerated. The blinded review of the data also indicates a substantial reduction in disease severity among two thirds of the patients, which may be attributed to AP1189. BioStock reached out to the company’s CEO Jeppe Øvlesen for a comment on the positive indicative results. 

Read the full interview with Synact Pharma's CEO Jeppe Øvlesen at biostock.se:

https://www.biostock.se/en/synact-comments-on-positive-phase-ii-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se